NCT05222516 2023-08-08
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
OM Pharma SA
Phase 2 Terminated
Clinical Trials
4 trialsNCT03738423 2022-06-10
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03736967 2021-11-01
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT02780167 2019-05-02
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Pfizer
Phase 2 Completed